We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multifaceted Intervention Reduces In-Patient Laboratory Costs

By LabMedica International staff writers
Posted on 16 Feb 2016
Print article
Image: A phlebotomist examining a blood sample to be used for multiple tests ordered by the physician (Photo courtesy of University of Utah Medical Center).
Image: A phlebotomist examining a blood sample to be used for multiple tests ordered by the physician (Photo courtesy of University of Utah Medical Center).
Image: Photomicrograph of a blood smear, part of the complete blood count (Photo courtesy of the University of Utah Medical Center).
Image: Photomicrograph of a blood smear, part of the complete blood count (Photo courtesy of the University of Utah Medical Center).
A tool called Value Driven Outcomes has been developed to reduce superfluous laboratory testing and when integrated into a quality improvement initiative laboratory costs decreased by nearly 10% per visit.

Unnecessary laboratory testing contributes to the estimated USD 910 billion wasted each year in health care in the USA. Beyond costs, laboratory testing is an important patient safety issue. The sheer number of tests ordered can lead to incidental findings that result in unnecessary follow-up testing and potentially harmful interventions, and early morning blood draws can prevent much needed rest. Vulnerable patients can even develop anemia and associated complications from over-testing.

Scientists at the University of Utah Medical Center (Salt Lake City, UT) carried out a retrospective, controlled, interrupted time series (ITS) study to evaluate the impact of a multifaceted laboratory reduction intervention on laboratory costs. Measurements were made of the primary outcomes of laboratory cost per day and per visit. Another measurement was the outcomes of number of basic metabolic panel (BMP), comprehensive metabolic panel (CMP), complete blood count (CBC), and prothrombin time/international normalized ratio tests per day; length of stay (LOS); and 30-day readmissions.

The results of the interventions over a 15-month period were tangible. An intervention group of 6,310 hospitalist patient visits were compared to a control group of 25,586 non-hospitalist visits. The interventions reduced the mean cost per day for laboratory testing from USD 138 to USD 123 and the mean cost per visit decreased from USD 618 to USD 558. There was also a significant reduction in laboratory cost per day, laboratory cost per visit, and the number of tests per day.

The authors concluded that a multifaceted approach, including education, rounding checklist implementation, cost feedback, and financial incentives, to laboratory reduction demonstrated a significant reduction in laboratory cost per day and per visit, as well as common tests per day at a major academic medical center.

Peter Yarbrough, MD, an assistant professor of internal medicine and lead author of the study, said, “Frequently, patients do need labs every morning, but that can create a culture where you're ordering tests without really thinking about what you're going to do with the results. Prior to VDO, we never had cost information. Most of the tests don't cost very much, but their numbers were so high that the total cost became significant.” The study was published on February 4, 2016, in the Journal of Hospital Medicine.

Related Links:

University of Utah Medical Center


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
H.pylori Test
Humasis H.pylori Card

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.